Natera, Inc. $NTRA Shares Sold by Eagle Health Investments LP

Eagle Health Investments LP reduced its position in Natera, Inc. (NASDAQ:NTRA) by 33.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 121,877 shares of the medical research company’s stock after selling 61,387 shares during the quarter. Natera makes up about 4.3% of Eagle Health Investments LP’s investment portfolio, making the stock its 6th biggest holding. Eagle Health Investments LP’s holdings in Natera were worth $24,374,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of NTRA. Robinhood Asset Management LLC acquired a new position in Natera in the fourth quarter worth $12,981,000. UBS Group AG increased its stake in Natera by 19.4% during the fourth quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock valued at $100,538,000 after purchasing an additional 71,355 shares during the last quarter. J. Safra Sarasin Holding AG acquired a new stake in shares of Natera during the fourth quarter worth $2,825,000. ABN Amro Investment Solutions raised its holdings in shares of Natera by 44.6% during the first quarter. ABN Amro Investment Solutions now owns 9,346 shares of the medical research company’s stock worth $1,869,000 after purchasing an additional 2,883 shares during the period. Finally, Aubrey Capital Management Ltd raised its holdings in shares of Natera by 32.1% during the fourth quarter. Aubrey Capital Management Ltd now owns 21,400 shares of the medical research company’s stock worth $4,902,000 after purchasing an additional 5,200 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Performance

NTRA stock opened at $258.03 on Tuesday. The stock has a market capitalization of $36.95 billion, a price-to-earnings ratio of -158.30 and a beta of 1.51. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $288.04. The stock’s fifty day moving average is $242.06 and its two-hundred day moving average is $221.57.

Analyst Ratings Changes

Several research firms have recently commented on NTRA. Morgan Stanley lifted their price target on shares of Natera from $250.00 to $310.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Wolfe Research assumed coverage on shares of Natera in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price objective on the stock. Sanford C. Bernstein initiated coverage on shares of Natera in a report on Friday, June 26th. They issued an “outperform” rating and a $310.00 target price on the stock. BTIG Research set a $275.00 target price on Natera and gave the company a “buy” rating in a research note on Wednesday, June 24th. Finally, JPMorgan Chase & Co. upped their target price on Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $267.83.

Insiders Place Their Bets

In other Natera news, Director Gail Boxer Marcus sold 11,000 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the transaction, the director directly owned 6,183 shares of the company’s stock, valued at $1,343,009.43. The trade was a 64.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Herm Rosenman sold 16,530 shares of the company’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the completion of the transaction, the director owned 4,250 shares of the company’s stock, valued at approximately $1,062,500. This trade represents a 79.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 167,171 shares of company stock worth $37,239,209. 5.05% of the stock is owned by company insiders.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.